Additionally, their drug was able to inhibit tumor growth in both subcutaneous and orthotopic xenograft mouse models inoculated with tumors from patients with PDAC KRASG12D and KRAS- that had relapsed after chemo- or radiotherapy [94]. The gene discussed is KRAS; the disease is neoplasm.